Nanobiotix (NASDAQ:NBTX) — Market Cap & Net Worth
Market Cap & Net Worth: Nanobiotix (NBTX)
Nanobiotix (NASDAQ:NBTX) has a market capitalization of $1.95 Billion ($1.95 Billion) as of August 3, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #6153 globally and #1953 in its home market, demonstrating a -2.95% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Nanobiotix's stock price $38.39 by its total outstanding shares 50785785 (50.79 Million). See Nanobiotix (NBTX) reinvestment ratio to understand how much of operating cash flow is reinvested back into capital assets.
Nanobiotix Market Cap History: 2020 to 2026
Nanobiotix's market capitalization history from 2020 to 2026. Data shows growth from $837.97 Million to $1.95 Billion (15.56% CAGR).
Index Memberships
Nanobiotix is a constituent of 2 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.46 Trillion | 0.08% | #161 of 976 |
|
NASDAQ Composite
IXIC
|
$40.26 Trillion | 0.00% | #692 of 3165 |
Weight: Nanobiotix's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Nanobiotix Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Nanobiotix's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
39.61x
Nanobiotix's market cap is 39.61 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2020 | $837.97 Million | $2.33 Million | -$33.59 Million | 360.42x | N/A |
| 2021 | $411.36 Million | $2.65 Million | -$47.00 Million | 155.41x | N/A |
| 2022 | $186.38 Million | $4.78 Million | -$57.04 Million | 39.03x | N/A |
| 2023 | $369.72 Million | $36.21 Million | -$39.70 Million | 10.21x | N/A |
| 2024 | $145.76 Million | $-7.19 Million | -$68.13 Million | -20.27x | N/A |
| 2025 | $1.17 Billion | $29.64 Million | -$23.96 Million | 39.61x | N/A |
Competitor Companies of NBTX by Market Capitalization
Companies near Nanobiotix in the global market cap rankings as of August 3, 2026.
Key companies related to Nanobiotix by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #220 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #424 globally with a market cap of $64.60 Billion USD.
- Argen-X (BR:ARGX): Ranked #543 globally with a market cap of $49.55 Billion USD ( €42.38 Billion EUR).
- UCB SA (BR:UCB): Ranked #563 globally with a market cap of $47.34 Billion USD ( €40.49 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #220 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $477.10 |
| #424 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $64.60 Billion | $762.63 |
| #543 | Argen-X | BR:ARGX | $49.55 Billion | €745.00 |
| #563 | UCB SA | BR:UCB | $47.34 Billion | €222.90 |
Nanobiotix Historical Marketcap From 2020 to 2026
Between 2020 and today, Nanobiotix's market cap moved from $837.97 Million to $ 1.95 Billion, with a yearly change of 15.56%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $1.95 Billion | +66.03% |
| 2025 | $1.17 Billion | +705.57% |
| 2024 | $145.76 Million | -60.58% |
| 2023 | $369.72 Million | +98.37% |
| 2022 | $186.38 Million | -54.69% |
| 2021 | $411.36 Million | -50.91% |
| 2020 | $837.97 Million | -- |
End of Day Market Cap According to Different Sources
On Aug 2nd, 2026 the market cap of Nanobiotix was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $1.95 Billion USD |
| MoneyControl | $1.95 Billion USD |
| MarketWatch | $1.95 Billion USD |
| marketcap.company | $1.95 Billion USD |
| Reuters | $1.95 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Nanobiotix
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small … Read more